Clinical Trial Update: Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports on safety and tolerability of a novel malathion formulation in children aged 6-24 months with head lice (pediculosis) in Phase 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head Lice Infestation
• Pediculosis

Drugs mentioned

• Malathion (malathion)

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Pediculosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-04-03